Navigation Links
Max Neeman International Initiates Large Phase IV Trial on Type II Diabetes with 25,000 Subjects Across 1,200 Sites
Date:9/30/2010

RESEARCH TRIANGLE PARK, N.C., Sept. 30 /PRNewswire/ -- A global pharmaceutical company has initiated a prospective trial to evaluate the impact of insulin guidelines developed by the Indian National Consensus group in collaboration with Max Neeman, a leading India-based Contract Research Organization. The goal is to provide simple management to the Type II Diabetes patient dependent on insulin.  The study will bring out a comparison between the routine clinical practice and the therapy decided as per the Insulin guidelines.

This large Phase IV study encompasses the northern, southern, western and eastern parts of India with over 1,200 sites and aims to enroll over 25,000 Type II Diabetics. Max Neeman is responsible for site management of all locations across the country and for achieving the enrollment target. To date, the team has successfully enrolled over 12,000 patients in 2 months time and will achieve the target before the stipulated time.

Max Neeman is experienced in endocrinology/metabolic studies having been awarded numerous diabetic trials to date with 98% patient retention rate and target enrollment met by the deadline.

About Max Neeman International

Max Neeman International is one of the leading CROs in India. Our specialty is that we offer services for the successful conduct of Phase I-IV clinical and device trials for small and mid-sized international and national Pharmaceutical, Biotechnology, Medical Device and Nutraceutical companies in compliance with ICH GCP standards. Operational since 2001, Max Neeman is an ISO 9001:2008 certified CRO for Monitoring, Site Management and Data Management Services. The company is presently active in over 31 cities with 6 regional offices.  Contact Donald Swankie, Vice President of Business Development via email to donald.swankie@neeman-medical.com or call +1.919.424.3345.  For more information please visit www.neeman-medical.com.


'/>"/>
SOURCE Max Neeman International
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Max Neeman International Expands Upon Cardiology and Device Trial Experience to Meet Increased Medical Device Development in India
2. Max Neeman International Expands Data Management Services with Conversion Into CDISC Standard Data Model
3. Max Neeman International and AMEDON Collaborate to Increase EDC Performance
4. Max Neeman International Expands Specialized Surgical Team for Clinical Trials
5. International Robotic Urology Symposium 2011
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Mindray Medical to Exhibit New Products at 64th China International Medical Equipment Fair
8. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
9. Webmedx and NLP International Team to Bring Natural Language Processing Software to Medical Transcription
10. MedWOW International Medical Equipment Platform Adds Seller Ministores
11. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
(Date:4/19/2017)... , April 19, 2017 ... stimulate an immune response in pets such as ... products are of various types such as Attenuated ... Toxoid Vaccines, DNA Vaccines and Recombinant Vaccines. Attenuated ... as virus or bacteria, which have been weakend ...
Breaking Medicine Technology:
(Date:4/28/2017)... Linda, Ca (PRWEB) , ... April 28, 2017 ... ... with cardiac or hERG liability could substantially improve drug safety and minimize the ... be provided for validating ion channel inhibition using cell lines and for cardiac ...
(Date:4/28/2017)... FL (PRWEB) , ... April 28, 2017 , ... ... Florida are conducting a pilot study of ActiGraph’s CentrePoint Data Hub ... is a leading provider of clinical-grade wearable activity and sleep monitoring solutions for ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... respiratory hospital, based in Denver, Colorado, announced an agreement to create the Jane ... continuing support of the Jane and Leonard Korman Family Foundation. The collaboration leverages ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). The ... retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. Fox ...
Breaking Medicine News(10 mins):